Presenting author

Daniel Gehrlach

2 presentations

• BH-200 (nelivaptan), a vasopressin V1b receptor antagonist, in genetically defined subgroups of MDD: Precision targeting of HPA-axis dysregulation in the OLIVE phase 2 program

  2026 ASCP Annual Meeting

• T25. BH-200 (nelivaptan), a vasopressin V1b receptor antagonist, in genetically defined subgroups of MDD: Precision targeting of HPA-axis dysregulation in the OLIVE phase 2 program

  2026 ASCP Annual Meeting